文献速递治疗药物监测与药物基因组学

甲氨蝶呤多聚谷氨酸与免疫介导炎症疾病疗效及毒性关系的荟萃分析

A meta-analysis of methotrexate polyglutamates in relation to efficacy and toxicity of methotrexate in inflammatory arthritis, colitis and dermatitis.
PubMed 文献 · Br J Clin Pharmacol · 2022-11-20

结果显示,在类风湿关节炎、幼年特发性关节炎和银屑病中,较高MTX-PG浓度与较低疾病活动度显著相关,且应答者MTX-PG浓度更高。这些发现为实施MTX治疗药物监测(TDM)迈出重要一步。

要点

  • 在RA和JIA中,较高MTX-PG与3个月和4个月后较低疾病活动度显著相关。
  • 银屑病中MTX-PG与疾病活动度呈负相关,应答者MTX-PG较高。
  • 该结果为MTX的TDM实施提供了证据支持。

核心结论

  • 在RA、JIA和银屑病中,较高的红细胞MTX-PG浓度与较低的疾病活动度相关。
  • 这些发现是朝着在IMIDs中实施MTX的TDM迈出的重要一步。

研究设计与样本

  • 研究覆盖炎症性关节炎(RA和JIA)、炎症性肠病(克罗恩病和溃疡性结肠炎)及皮炎(银屑病和特应性皮炎)。

主要发现

  • 在RA和JIA中,较高MTX-PG与3个月时较低疾病活动度显著相关(β:-0.002;95%CI:-0.004至-0.001)。
  • 在RA和JIA中,较高MTX-PG与MTX使用4个月后较低疾病活动度显著相关(β:-0.003;95%CI:-0.005至-0.002)。
  • 在银屑病中,较高MTX-PG与较低疾病活动度相关(R:-0.82;95%CI:-0.976至-0.102)。
  • 在RA、JIA和银屑病应答者中观察到较高的MTX-PG(平均差:5.2 nmol/L MTX-PGtotal;P < .01)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: In immune-mediated inflammatory diseases (IMIDs), early symptom control is a key therapeutic goal. Methotrexate (MTX) is the first-line treatment across IMIDs. However, MTX is underutilized and suboptimally dosed, partly due to the inability of making individualized treatment decisions through therapeutic drug monitoring (TDM). To implement TDM in clinical practice, establishing a relationship between drug concentration and disease activity is paramount. In this meta-analysis, we investigated the relationship between concentrations of MTX polyglutamates (MTX-PG) in erythrocytes and efficacy as well as toxicity across IMIDs. METHODS: Studies analysing MTX-PG in relation to disease activity and/or toxicity were included for inflammatory arthritis (rheumatoid [RA] and juvenile idiopathic arthritis [JIA]), inflammatory bowel disease (Crohn's and ulcerative colitis) and dermatitis (psoriasis and atopic dermatitis). Meta-analyses were performed resulting in several summary effect measures: regression coefficient (β), correlation coefficient and mean difference (of MTX-PG in responders vs. nonresponders) for IMIDs separately and collectively. RESULTS: Twenty-five studies were included. In RA and JIA, higher MTX-PG was significantly associated with lower disease activity at 3 months (β: -0.002; 95% confidence interval [CI]: -0.004 to -0.001) and after 4 months of MTX use (β: -0.003; 95% CI: -0.005 to -0.002). Similarly, higher MTX-PG correlated with lower disease activity in psoriasis (R: -0.82; 95% CI: -0.976 to -0.102). Higher MTX-PG was observed in RA, JIA and psoriasis responders (mean difference: 5.2 nmol/L MTX-PGtotal ; P < .01). CONCLUSION: We showed that higher concentrations of erythrocyte MTX-PG were associated with lower disease activity in RA, JIA and psoriasis. These findings are an important step towards implementation of TDM for MTX treatment across IMIDs.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. van de Meeberg MM, Hebing RCF, Nurmohamed MT, et al. A meta-analysis of methotrexate polyglutamates in relation to efficacy and toxicity of methotrexate in inflammatory arthritis, colitis and dermatitis. Br J Clin Pharmacol. 2022. PMID: 36326810. doi:10.1111/bcp.15579

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。